DLBCL with rearrangements involving MYC and BCL2/BCL6, which upregulate MYC gene expression, are referred to as double hit or triple hit lymphomas, and are associated with inferior progression free survival and overall survival in patients receiving traditional R-CHOP therapy (Hummel et al., 2006; Savage et al., 2009; Valera et al., 2013; Rosenquist et al., 2017). Here, BCL6 is linked to lymphoma.